Standard Starting Dose for Dupixent in Atopic Dermatitis
For adults with moderate to severe atopic dermatitis, the standard starting dose of Dupixent (dupilumab) is 600 mg (administered as two 300 mg subcutaneous injections), followed by 300 mg every 2 weeks. 1
Adult Dosing
- The initial loading dose is 600 mg given as two separate 300 mg subcutaneous injections 2, 1
- Maintenance dosing is 300 mg every 2 weeks (Q2W) following the loading dose 2, 1
- This regimen is FDA-approved and represents the standard dosing for adults 1
Pediatric Dosing Considerations
For pediatric patients 6 years and older, dosing is weight-based 1:
- 15 to <30 kg: 600 mg loading dose (two 300 mg injections), then 300 mg every 4 weeks 1
- 30 to <60 kg: 400 mg loading dose (two 200 mg injections), then 200 mg every 2 weeks 1, 3
- ≥60 kg: 600 mg loading dose (two 300 mg injections), then 300 mg every 2 weeks 1, 3
For children 6 months to 5 years, no loading dose is used 1:
Administration Details
- Dupixent is administered via subcutaneous injection into the thigh, abdomen (avoiding 2 inches around the navel), or upper arm (if administered by a caregiver) 1
- When giving the loading dose, administer each injection at different injection sites 1
- Rotate injection sites with each subsequent dose 1
Clinical Context and Efficacy
The 2024 American Academy of Dermatology guidelines identify dupilumab as the preferred first-line systemic agent for moderate to severe atopic dermatitis, with all guideline workgroup members favoring it over other systemic therapies 2. This standard dosing regimen (600 mg loading, then 300 mg Q2W) has demonstrated:
- Excellent safety profile in clinical trials with over 5 years of clinical practice data 2
- Significant improvements in disease severity, quality of life, and pruritus compared to placebo 2
- Comparable efficacy to upadacitinib 15 mg daily and superior efficacy to abrocitinib 100 mg daily 2